# A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

> **NCT04091360** · PHASE2 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 40 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Part A: RPL554
- **DRUG:** Placebos
- **DRUG:** Part B: RPL554

## Key facts

- **NCT ID:** NCT04091360
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2020-12-10
- **Final completion:** 2021-01-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091360, "A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04091360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*